Blog
Bringing a drug to market: How do we find and monitor suitable patients?
What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world.
web-based testing,
wearables,
voice recognition,
voice,
virtual clinical trials,
technology,
swm,
stress,
social cognition,
smartphones,
schizophrenia,
safety,
rvp,
rti,
research funding,
research,
remote testing,
recruitment,
psychosis,
prodromal,
pro-cognitive,
prm,
press release,
presenteeism,
precision psychiatry,
poster,
personalised medicine,
patient-centric,
patient recruitment,
parkinson's disease,
pal,
ots,
occupational health,
nutrition,
neuroscience,
near-patient testing,
multiple sclerosis,
mts,
ms,
mental wellbeing,
mental health,
mdd,
mci,
major depression,
machine learning,
life at cambridge cognition,
jobs at cambridge cognition,
international women's day,
ied,
hot cognition,
healthcare,
grant,
funding,
fatigue,
ert,
epidemiology,
emotion recognition,
ecoa,
ebt,
early career researchers,
early alzheimer's disease,
dms,
digital tools,
digital health,
depression,
dementia,
covid-19,
cognitive testing,
cognitive science,
cognitive safety,
cognitive research,
cognitive impairment,
cognitive function,
cognitive dysfunction,
cognitive biomarkers,
cognitive assessment,
cognition kit,
cognition,
cns summit,
clinical trials,
cias,
chronic illness,
chronic health conditions,
cgt,
cantab testimonial,
cantab research grant,
cantab for clinical trials,
cantab,
cambridge cognition,
brain health,
bipolar disorder,
biomarkers,
automatic speech recognition,
attention,
alzheimer's disease,
affective cognition,
academic,
absenteeism,
aaic2020,
aaic,
